Results for tag: "Basal Cell Nevus Syndrome Drug"

Basal Cell Nevus Syndrome (BCNS) is a rare genetic disorder that affects the skin, eyes, and bones. It is caused by a mutation in the PTCH1 gene, which is responsible for regulating cell growth and differentiation. The most common symptom of BCNS is multiple basal cell carcinomas (BCCs), which are the most common type of skin cancer. Treatment for BCCs typically involves surgery, radiation therapy, and topical medications. The BCNS Drug market is composed of a variety of drugs used to treat BCCs. These include topical medications such as imiquimod, fluorouracil, and ingenol mebutate, as well as systemic medications such as vismodegib and sonidegib. These drugs are used to reduce the size of tumors, reduce inflammation, and prevent the spread of cancer cells. Some of the companies in the BCNS Drug market include Novartis, Pfizer, Merck, and GlaxoSmithKline. These companies produce a variety of medications used to treat BCCs, including topical medications, systemic medications, and combination therapies. Additionally, there are several smaller companies that specialize in developing and manufacturing BCNS drugs. Show Less Read more